Concerta XL 36 mg prolonged-release tablets

País: Irlanda

Idioma: inglés

Fuente: HPRA (Health Products Regulatory Authority)

Cómpralo ahora

Ficha técnica Ficha técnica (SPC)
17-04-2015

Ingredientes activos:

Methylphenidate hydrochloride

Disponible desde:

Imbat Limited

Código ATC:

N06BA; N06BA04

Designación común internacional (DCI):

Methylphenidate hydrochloride

Dosis:

36 milligram(s)

formulario farmacéutico:

Prolonged-release tablet

Vía de administración:

Oral use

Unidades en paquete:

30 prolonged-release tablets

tipo de receta:

Product subject to prescription which may not be renewed (A)

Fabricado por:

Janssen Pharmaceutica NV

Grupo terapéutico:

Centrally acting sympathomimetics

Área terapéutica:

Centrally acting sympathomimetics; methylphenidate

indicaciones terapéuticas:

It is indicated as part of a comprehensive treatment programme for Attention Deficit Hyperactivity Disorder (ADHD) in children aged 6 years of age and over

Estado de Autorización:

Authorised

Fecha de autorización:

2015-04-02

Información para el usuario

                                Page 1 of 2
PACKAGE LEAFLET: INFORMATION FOR THE USER
CONCERTA
® XL 36MG
PROLONGED-RELEASE TABLETS
(methylphenidate hydrochloride)
The name of your medicine is Concerta XL, it contains the active
substance ‘methylphenidate hydrochloride’.
The name ‘methylphenidate’ will also be used in this leaflet.
IMPORTANT THINGS YOU NEED TO KNOW ABOUT YOUR
MEDICINE
THIS MEDICINE IS USED TO TREAT ADHD

The full name for ADHD is ‘Attention Deficit Hyperactivity
Disorder’.

The medicine helps with your brain activity. It can help
improve your attention, help you concentrate, and make you
less impulsive.

You need to have other treatments for ADHD as well as this
medicine.
Read Section 1 for more information.
BEFORE YOU TAKE THIS MEDICINE, TALK TO YOUR DOCTOR IF:

You have heart, circulation, or mental health problems - you
may not be able to take this medicine.

You are taking any other medicines - this is because
methylphenidate can affect how other medicines work.
Read Section 2 for more information.
WHILE TAKING THIS MEDICINE:

See your doctor regularly. This is because your doctor will
want to check how the medicine is working.

Do not stop taking the medicine without first talking to your
doctor.

Your doctor may stop your medicine to see if it is still
needed, if you take it for more than a year.

The most common side effects are feeling nervous, not
being able to sleep or having a headache.
Read Sections 3 and 4 for more information.
TALK TO YOUR DOCTOR STRAIGHT AWAY IF ANY OF THE
FOLLOWING HAPPEN:

Your mood and how you feel changes.

You feel any problems with your heart.
Read Section 4 for more information.
THE REST OF THIS LEAFLET INCLUDES MORE DETAIL AND
OTHER IMPORTANT INFORMATION ON THE SAFE AND
EFFECTIVE USE OF THIS MEDICINE.

Keep this leaflet. You may need to read it again.

If you have any further questions, ask your doctor or
pharmacist.

This medicine has been prescribed for you only. Do not pass
it on to others. It may harm them, even if their signs of
i
                                
                                Leer el documento completo
                                
                            

Ficha técnica

                                SUMMARY OF PRODUCT CHARACTERISTICS
1 NAME OF THE MEDICINAL PRODUCT
Concerta XL 36 mg prolonged-release tablets
2 QUALITATIVE AND QUANTITATIVE COMPOSITION
One prolonged-release tablet contains 36 mg of methylphenidate
hydrochloride.
Excipients with known effect: contains lactose.
For the full list of excipients, see section 6.1.
3 PHARMACEUTICAL FORM
Prolonged-release tablet.
_Product imported from Germany:_
Capsule-shaped, white tablet with “alza 36” printed on one side in
black ink.
4 CLINICAL PARTICULARS
As per PA0748/049/002
5 PHARMACOLOGICAL PROPERTIES
As per PA0748/049/002
6 PHARMACEUTICAL PARTICULARS
6.1 LIST OF EXCIPIENTS
Butylhydroxytoluene (E321)
Cellulose acetate
Hypromellose (E464)
Phosphoric acid 85%
Poloxamer 188
Macrogol 200 000 and 7000 000,
Povidone K29-32
Sodium chloride
Stearic acid
Succinic acid
Iron oxide black (E172)
Iron oxide hydrate (E172)
FILM COAT:
Hypromellose (E464)
Lactose monohydrate
Titanium dioxide (E171)
Triacetin
CLEAR COAT:
Carnauba wax
Hypromellose (E464)
H
E
A
L
T
H
P
R
O
D
U
C
T
S
R
E
G
U
L
A
T
O
R
Y
A
U
T
H
O
R
I
T
Y
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
_D_
_a_
_t_
_e_
_ _
_P_
_r_
_i_
_n_
_t_
_e_
_d_
_ _
_0_
_2_
_/_
_0_
_4_
_/_
_2_
_0_
_1_
_5_
_C_
_R_
_N_
_ _
_2_
_1_
_5_
_0_
_5_
_6_
_6_
_p_
_a_
_g_
_e_
_ _
_n_
_u_
_m_
_b_
_e_
_r_
_:_
_ _
_1_
Macrogol 400
PRINTING INK:
Iron oxide black (E172)
Hypromellose (E464)
Isopropyl alcohol
Propylene glycol
Purified water
6.2 INCOMPATIBILITIES
Not applicable.
6.3 SHELF LIFE
The shelf life expiry date of this product is the date shown on the
inner packaging and outer carton of the product as
marked in the c
                                
                                Leer el documento completo